Australia · Delayed Price · Currency is AUD Botanix Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Sofdra prescriptions and revenue continue to grow, with March 2026 setting a new record. Strong cash position, cost discipline, and a new API supplier are expected to drive future margin expansion and mitigate tariff risks. The platform is well-positioned for additional product launches.
-
Sofdra prescriptions and revenue surged in the first half of FY2026, driven by strong sales force execution and a scalable fulfillment platform. A major capital raise is underway to fund growth, reduce COGS, and support expansion, with profitability targeted as platform efficiencies scale.
-
Revenue and prescriptions for Sofdra grew strongly, with net revenue up 28% quarter-over-quarter and gross-to-net yield improving to 24%. Sales force expansion and a unique fulfillment platform are driving growth, while cost-saving initiatives and high physician intent to prescribe support a positive outlook.
-
Q1 saw robust growth in Sofdra prescriptions and net sales, driven by an expanded sales force and strong fulfillment platform. Cost management improved margins and liquidity, with all resources focused on Sofdra's success and further market penetration.
Fiscal Year 2025
-
Q4 FY2025 saw a successful Sofdra launch, with gross sales up to $20.4M and net revenue at $4.3M, driven by rapid prescription growth and high refill rates. The company is well-funded, expanding its sales force, and expects to reach profitability without further capital needs.
Fiscal Year 2024
-
Sofdra’s commercial launch is set for early 2025, leveraging a robust AI-powered digital and telemedicine platform to target the large, underserved hyperhidrosis market. Early patient engagement, strong reimbursement outlook, and scalable infrastructure position the product for rapid uptake and future portfolio expansion.